PBLS (Parabilis Medicines) Additional Paid-In Capital: $15.01 Mil(As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $38.85
! 2 Warning Signs
View Full Analysis

What is Parabilis Medicines Additional Paid-In Capital?

Parabilis Medicines PBLS -2.71% 10 Additional Paid-In Capital is $15.01 Mil as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.


Parabilis Medicines's quarterly additional paid-in capital increased from . 20 ($0.00 Mil) to Dec. 2024 ($11.66 Mil) and increased from Dec. 2024 ($11.66 Mil) to Dec. 2025 ($15.01 Mil).

Parabilis Medicines's annual additional paid-in capital increased from . 20 ($0.00 Mil) to Dec. 2024 ($11.66 Mil) and increased from Dec. 2024 ($11.66 Mil) to Dec. 2025 ($15.01 Mil).

Parabilis Medicines Additional Paid-In Capital Related Terms

Parabilis Medicines Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines Additional Paid-In Capital Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
Additional Paid-In Capital
11.66 15.01

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
Additional Paid-In Capital 11.66 15.01
PBLS
10GF Score
Parabilis Medicines Inc PBLS
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $15.01 Mil mean?
Parabilis Medicines (PBLS) has a Additional Paid-In Capital of $15.01 Mil as of Dec. 2025. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Parabilis Medicines and its competitors.
Is Parabilis Medicines' Additional Paid-In Capital too high?
Parabilis Medicines' current Additional Paid-In Capital is $15.01 Mil. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Additional Paid-In Capital compare to DYN and ACAD?
Parabilis Medicines' Additional Paid-In Capital of $15.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Parabilis Medicines and its competitors. Parabilis Medicines's current Additional Paid-In Capital is $15.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Additional Paid-In Capital of $15.01 Mil. The current Additional Paid-In Capital is $15.01 Mil. Parabilis Medicines' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Additional Paid-In Capital is $15.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.85
Price